The PE Ratio as of July 2024 (TTM) for Emergent BioSolutions Inc. (EBS) is -1.27

According to Emergent BioSolutions Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.27. This represents a change of -332.62% compared to the average of 0.55 of the last 4 quarters.

Emergent BioSolutions Inc. (EBS) Historical PE Ratio (quarterly & annually)

How has EBS PE Ratio performed in the past?

The mean historical PE Ratio of Emergent BioSolutions Inc. over the last ten years is 22.28. The current -1.27 PE Ratio has changed -669.93% with respect to the historical average. Over the past ten years (40 quarters), EBS's PE Ratio was at its highest in in the June 2021 quarter at 183.49. The PE Ratio was at its lowest in in the December 2018 quarter at -221.86.

Emergent BioSolutions Inc. (EBS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Emergent BioSolutions Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Emergent BioSolutions Inc. (EBS) Average PE Ratio

How has EBS PE Ratio performed in the past?

The current PE Ratio of Emergent BioSolutions Inc. (EBS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Emergent BioSolutions Inc. (EBS) PE Ratio vs. Peers

How is EBS’s PE Ratio compared to its peers?

Emergent BioSolutions Inc.’s PE Ratio is less than Zoetis Inc. (34.45), less than PetIQ, Inc. (87.34), greater than Bausch Health Companies Inc. (-106.07), less than Neurocrine Biosciences, Inc. (39.63), less than Akanda Corp. (-0.16), greater than Lifecore Biomedical, Inc. (-3.65), less than Prestige Consumer Healthcare Inc. (16.83), greater than Intra-Cellular Therapies, Inc. (-70.24), less than Indivior PLC (0), less than Alkermes plc (16.25), greater than Cumberland Pharmaceuticals Inc. (-2.46), greater than Deciphera Pharmaceuticals, Inc. (-11.74), less than Collegium Pharmaceutical, Inc. (12.50), greater than DURECT Corporation (-2.20),

Build a custom stock screener for Emergent BioSolutions Inc. (EBS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Emergent BioSolutions Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Emergent BioSolutions Inc. (EBS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Emergent BioSolutions Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.